Introduction {#sec1}
============

Methuosis is a form of nonapoptotic cell death triggered by alterations in the trafficking of clathrin-independent endosomes and is associated with vacuolization of macropinosome and endosome compartments.^[@ref1]^ Methuosis was initially defined in glioblastoma cells expressing activated Ras,^[@ref2]^ but several studies have reported the features of methuosis in a broad spectrum of cancer cells including gastric carcinoma cells and osteosarcoma cells.^[@ref3],[@ref4]^ The vacuoles generated during methuosis are distinct from autophagosomes and show characteristics of enlarged macropinosomes. Vacuolated cells eventually undergo caspase-independent cell death initiated by the dysregulation of micropinocytosis.^[@ref2]^

Previous investigations found that indolyl-pyridinyl-propenones (also referred to as indole-based chalcones) trigger methuosis.^[@ref5]^ Specifically, 3-(5-methoxy-2-methyl-1*H*-indol-3-yl)-1-(4-pyridinyl)-2-propene-1-one (MOMIPP) was identified as an initial exemplar tool compound. Follow-up structure--activity relationship (SAR) studies defined key features associated with three phenotypic classifications, namely, the induction of methuosis, vacuolization without cell death,^[@ref6]^ and disruption of microtubules leading to apoptosis.^[@ref7]^ Selected substitutions on the indole at position 2 or moving the methoxy group from position 5 to 6^[@ref8]^ redirected the mode of cytotoxicity from distinctive methuosis to microtubule disruption with little observable effect on vacuoles. However, the protein target(s) of the compounds that prompt the methuosis phenotype have not been identified. In this study, we identified PIKFYVE, a class III phosphoinositide (PI) kinase, as at least one candidate protein that when inhibited triggers vacuolization, a hallmark of methuosis.

PI homeostasis is tightly regulated because the spatiotemporal restriction of different PI species is crucial for membrane trafficking within both the secretory and endocytic pathways.^[@ref9],[@ref10]^ Disruption of endosome or macropinosome trafficking has been shown to induce cellular vacuolization.^[@ref11]^ PI synthesis involves phosphorylating/dephosphorylating positions D3, D4, and/or D5 of their inositol ring by various lipid kinases and phosphatases.^[@ref10]^ Accordingly, the inhibition of select lipid kinases or phosphatases by chemical or genetic perturbation can induce cellular vacuolization.^[@ref12],[@ref13]^

Results and Discussion {#sec2}
======================

To explore whether indolyl-pyridinyl-propenones disrupt PI homeostasis by inhibiting a specific inositol kinase or phosphatase, we used a competition binding assay to quantitatively measure interactions between the lead compound MOMIPP and 22 inositol kinases including clinically relevant mutants ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The competition binding assay showed that at 10 μM, MOMIPP competes away all binding of inositol kinases PIKFYVE and PIP5K1C as compared to the control.

###### Lipid Kinase Competition Assay for 22 Inositol Kinases Including Clinically Relevant Mutants[a](#t1fn1){ref-type="table-fn"}

  target           \% control
  ---------------- ------------
  PIK3C2B          76
  PIK3C2G          39
  PIK3CA           99
  PIK3CA(C420R)    100
  PIK3CA(E542K)    98
  PIK3CA(E545A)    82
  PIK3CA(E545K)    81
  PIK3CA(H1047L)   72
  PIK3CA(H1047Y)   92
  PIK3CA(I800L)    72
  PIK3CA(M1043I)   98
  PIK3CA(Q546K)    82
  PIK3CB           46
  PIK3CD           66
  PIK3CG           54
  PIK4CB           87
  PIKFYVE          0
  PIP5K1A          61
  PIP5K1C          0
  PIP5K2B          96
  PIP5K2C          66
  VPS34            50

MOMIPP (10 μM ) was used for the competition. Data are shown as % control, where lower numbers indicate more competition between the control compound and MOMIPP. % control was calculated as follows. (MOMIPP signal -- positive control signal)/(negative control signal -- positive control signal) × 100. Negative control = DMSO (100% control); positive control = control compound that binds specifically to each kinase (0% control).

To further assess the binding potency and specificity, we calculated binding constants (*K*~d~) against PIKFYVE and PIP5K1C with a standard dose--response curve ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). In this assay, MOMIPP exhibited a *K*~d~ of 5.3 nM against PIKFYVE, whereas the *K*~d~ against PIP5K1C was \>15 000 nM, suggesting that MOMIPP specifically binds PIKFYVE with strong potency. Because previous SAR studies^[@ref7]^ of methuosis-inducing activity resulted in three classes of indolyl-pyridinyl-propenones with distinct cellular phenotypes, we synthesized compounds from each class to confirm cellular phenotypes and characterize PIKFYVE inhibition ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

![Lipid kinase competition assay for PIKFYVE and PIP5K1C. Compound--kinase interactions were quantitated by quantitative PCR (qPCR) that detects the associated DNA label on each kinase as described in the [Experimental Section](#sec3){ref-type="other"}. The amount of kinase measured by qPCR is plotted against the corresponding MOMIPP concentration. Binding constants (*K*~d~) were calculated with a standard dose--response curve using the Hill equation^[@ref12]^ as follows. Response = background + (signal -- background)/(1 + (*K*~d~^Hill slope^)/(dose^Hill slope^)). The Hill slope was set to −1.](ao-2018-00202h_0001){#fig1}

###### Summary of Compound Activity[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-00202h_0006){#GRAPHIC-d269e486-autogenerated}

  compounds         class   R~1~               R~2~            vacuolization   cell death   *K*~d~ (PIKFYVE) (nM)
  ----------------- ------- ------------------ --------------- --------------- ------------ -----------------------
  **2a**            1       H~3~CH~2~CO        CH~3~           yes             no           23
  **2c**            1       (H~3~C)~2~HCO      CH~3~           yes             no           51
  **1a** (MOMIPP)   2       H~3~CO             CH~3~           yes             yes          6.9
  **2b**            2       H~3~C(H~2~C)~2~O   CH~3~           yes             yes          6.5
  **2l**            3       H~3~CO             COOCH~2~CH~3~   no              yes          540
  **2o**            N/A     H~3~CO             COOH            no              no           46

N/A: not assigned. Compound code numbers were assigned as previously reported.^[@ref7]^

As previously characterized,^[@ref7]^ class 1 compounds (**2a**, **2c**) induced cellular vacuolization without causing cell death, class 2 compounds (**1a**; MOMIPP, **2b**) induced cellular vacuolization and cell death via methuosis, and class 3 compounds (**2l**) induced cell death without showing distinct cellular vacuolization, consistent with prior reports of tubulin modulation ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). To explore the correlation between the cellular vacuolization phenotype and the binding activity against PIKFYVE, we calculated binding constants (*K*~d~) against PIKFYVE with a standard dose--response curve.

![Effects of selected indolyl-pyridinyl-propenones on cell viability. Percent viability relative to vehicle \[dimethyl sulfoxide (DMSO)\] control after treatment for 72 h with indicated concentrations of compounds. Error bars indicate mean ± SD of at least three replicates.](ao-2018-00202h_0002){#fig2}

![Vacuolization phenotype of compounds and its correlation to the PIKFYVE binding activity. Phase contrast images of live cells were obtained at 2 and 24 h after compound treatment as described in the [Experimental Section](#sec3){ref-type="other"} at 40× magnification. The PIKFYVE binding assay with each compound was performed as described.](ao-2018-00202h_0003){#fig3}

In this assay, class 1 compounds (**2a**, **2c**) exhibited *K*~d~ of 23 and 51 nM, respectively, and class 2 compounds (**1a**; MOMIPP, **2b**) exhibited *K*~d~ of 6.9 and 6.5 nM, respectively, whereas the *K*~d~ of class 3 compound (**2l**) was \>500 nM. The *K*~d~ of free acid compound (**2o**) was 46 nM ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). These results show that compounds with the cellular vacuolization phenotype (class 1 and 2) strongly bind PIKFYVE. Compounds with carboxylic acid substitutions at R~2~ (class 3) do not show the cellular vacuolization phenotype. Compound **2l**, a tubulin modulator,^[@ref7]^ displays a weak binding activity against PIKFYVE but triggers cell death. The related compound (**2o**) binds PIKFYVE with strong in vitro potency but likely loses the cellular activity because of the limited cellular permeability.

PIKFYVE is a 240 kD lipid kinase that phosphorylates the D-5 position in endosomal phosphatidylinositol-3-phosphate (PI3P) to yield 3,5-bisphosphate (PI(3,5)P2).^[@ref14]^ To determine whether MOMIPP directly inhibits the PIKFYVE kinase activity, we performed an in vitro kinase assay with the purified PIKFYVE full-length protein. MOMIPP potently inhibited the PIKFYVE kinase activity (IC~50~ = 5.05 nM), whereas the class 3 compound (**2l**) had a reduced activity (IC~50~ = 446 nM) toward PIKFYVE ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). This result is consistent with the PIKFYVE binding assay where MOMIPP showed a stronger binding activity (*K*~d~ = 6.9 nM) in comparison to the class 3 compound (**2l**) (*K*~d~ = 540 nM) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

![PIKFYVE inhibition by MOMIPP. The PIKFYVE inhibitory activity by compounds **1a** (MOMIPP) and **2l** was measured as described in the [Experimental Section](#sec3){ref-type="other"}. Data are shown as percent inhibition of kinase activity calculated from the percent conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP).](ao-2018-00202h_0004){#fig4}

The genetic manipulation of PIKFYVE with CRISPR (clustered regularly interspaced short palindromic repeats)-mediated genome editing ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A) and chemical perturbation of PIKFYVE activity using apilimod ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B) also showed similar vacuolization. These results effectively demonstrate that MOMIPP and its analogues (class 1 and class 2 compounds) trigger cellular vacuolization by inhibiting the PIKFYVE kinase activity.

![Genetic and chemical perturbations of PIKFYVE phenocopies the MOMIPP treatment. (A) Phase contrast images of HCT116 cells stably expressing scrambled single-guide RNA (sgRNA) or sgRNA targeting PIKFYVE. (B) Phase contrast images of HCT116 cells treated with DMSO or 5 nM PIKFYVE inhibitor apilimod for 24 h.](ao-2018-00202h_0005){#fig5}

In conclusion, we showed that MOMIPP binds PIKFYVE and inhibits its kinase activity. The preliminary SAR study effectively demonstrates that the binding and inhibitory activity of MOMIPP analogues against PIKFYVE determines their biological activity in cellular vacuolization, which is a hallmark of methuosis.^[@ref1]^ The cytotoxic activity of MOMIPP (**1a**) and **2b** may have additional target(s) and has unique pleiotropic effects on cells that lead to metabolic collapse and cell death.^[@ref6]^ We showed that the inhibition of the PIKFYVE kinase activity results in cellular vacuolization, which is a contributing factor to methuosis.

PIKFYVE has also been reported to regulate TLR (toll-like receptor)-induced IL-12/23 expression by modulating PI(3)P and PI(3,5)P2 levels, and dysregulated TLR signaling can lead to autoimmune diseases such as Crohn's disease, rheumatoid arthritis, and psoriasis.^[@ref13]^ Our study suggests that MOMIPP might be an important tool to study the function of the PIKFYVE lipid kinase activity in various biological processes including the TLR pathway regulation in IL-12/23-mediated diseases as well as methuosis.

Experimental Section {#sec3}
====================

General Chemistry {#sec3.1}
-----------------

All commercially available solvents (VWR and Fisher) and compounds (Fluka, Lancaster, Aldrich) were used as received. Compounds were synthesized according to the reported experimental procedures ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00202/suppl_file/ao8b00202_si_001.pdf)).^[@ref7]^ NMR spectra were recorded with a Bruker AV 400 spectrometer in the solvents indicated. Chemical shifts (δ) are given in ppm relative to trimethylsilane. All coupling constants (*J*) are reported in hertz. The data are reported as follows: chemical shift, intergration, and multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and b = broad peak). High-resolution mass spectrometry (HRMS) was performed using electrospray ionization (ESI) in positive ion mode after separation by liquid chromatography (Nexera from Shimadzu). The elemental composition was derived from the mass spectra acquired at the high resolution of about 30 000 on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). The high mass accuracy below 1 ppm was obtained by using a lock mass. Preparatory silica gel chromatography was performed on a CombiFlash Rf 200 (Teledyne ISCO) flash chromatography system with RediSep Rf normal phase silica gel (25--70 μm) columns and 254 nm UV detection.

To determine the chemical purity of final compounds, reverse-phase high-performance liquid chromatography (HPLC) analysis was performed. An ACQUITY UPLC HSS T3 column (1.8 μm; 2.1 × 100 mm) and a mobile phase (0.8 mL/min flow rate) were used with the following composition: eluent A (water + 0.05% formic acid + 3.75 mM acetic acid), eluent B (acetonitrile + 0.04% formic acid), with gradient elution from 5 to 98% eluent B. HPLC was performed at 60 °C. As determined by HPLC, all compounds were of 95% or of a greater purity. Mass spectra were obtained with a Finnigan MAT 8200 (70 eV) spectrometer with an ESI-MS source: Finnigan MAT 95 for accurate mass determination. The mass spectra (*m*/*z*) were recorded using ESI.

Synthetic Protocols {#sec3.2}
-------------------

### 5-Methoxy-2-methyl-\[1*H*\]-indole-3-carbaldehyde (**4**) {#sec3.2.1}

To a dried two-neck round-bottom flask, flushed under argon at 0 °C, POCl~3~ (0.25 mL, 2.68 mmol) was added to a solution of anhydrous dimethylformamide (DMF) (1 mL) and stirred for 10 min before the dropwise addition of a solution of 5-methoxy-2-methyl-\[1*H*\]-indole (100 mg, 0.620 mmol) dissolved in anhydrous DMF (2 mL). The reaction mixture was then warmed to room temperature and stirred for an additional 30 min. NaOH (1 N, 5 mL) was added slowly, and the aqueous layer was extracted with dichloromethane (DCM) (2 × 25 mL). The organic phases were combined, dried over Na~2~SO~4~, and concentrated under a reduced pressure to yield the corresponding compound (**4**) as a colorless oil (107 mg, 82%). LC/MS (ESI) *m*/*z*: (M + H)^+^ 190.2. The compound was taken to the next step without further purification.

### (*E*)-3-(5-Methoxy-2-methyl-\[1*H*\]-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (**1a**) {#sec3.2.2}

To a solution of **4** (105 mg, 0.555 mmol) in anhydrous MeOH (3 mL), pyrrolidine (0.101 mL, 1.221 mmol) and 4-acetylpyridine (168 mg, 1.387 mmol) were added. The mixture was then heated at 65 °C for 24 h. As the reaction progressed, a precipitate was formed. When the reaction was complete, the precipitate was collected, washed with ice-cold MeOH (3 × 10 mL), and dried at room temperature for 24 h to yield **1a** as a red solid (111.3 mg, 68%): ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.90 (s, 1H), 8.85--8.78 (m, 2H), 8.09 (d, *J* = 15.3 Hz, 1H), 7.98--7.91 (m, 2H), 7.44 (d, *J* = 2.3 Hz, 1H), 7.41--7.28 (m, 2H), 6.85 (dd, *J* = 8.7, 2.3 Hz, 1H), 3.87 (s, 3H), 2.58 (s, 3H). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 188.01, 155.13, 150.56, 145.73, 145.06, 139.54, 130.98, 126.55, 121.37, 112.77, 112.23, 110.86, 109.26, 103.47, 12.13. HPLC (10 min): tR = 3.28 min, HPLC purity 100%. LC/MS (ESI) *m*/*z*: (M + H)^+^ 293.2; HRMS (EI) *m*/*z*: 293.12845 \[M + H\]^+^ calcd for C~18~H~17~O~2~N~2~, 293.12845; found, 293.12845.

### (*E*)-3-(5-Ethoxy-2-methyl-1*H*-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (**2a**) {#sec3.2.3}

In a 20 mL pressure-release vial, 5-ethoxy-2-methyl-1*H*-indole-3-carbaldehyde **4a** (50 mg, 0.25 mmol) was dissolved in anhydrous MeOH (2 mL), followed by the addition of 4-acetylpyridine (74.5 mg, 0.62 mmol) and piperidine (0.054 mL, 0.54 mmol). The solution was then heated at 65 °C for 24 h. The reaction mixture was diluted with DCM and purified using silica gel flash chromatography (0--100% EtOAc in heptane) to yield an orange solid (9.7 mg, 13%): ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.88 (s, 1H), 8.88--8.73 (m, 2H), 8.07 (d, *J* = 15.3 Hz, 1H), 7.99--7.88 (m, 2H), 7.41 (d, *J* = 2.3 Hz, 1H), 7.37--7.26 (m, 2H), 6.83 (dd, *J* = 8.7, 2.3 Hz, 1H), 4.13 (q, *J* = 7.0 Hz, 2H), 2.57 (s, 3H), 1.37 (t, *J* = 6.9 Hz, 3H). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 188.16, 154.40, 145.77, 145.18, 139.63, 131.00, 126.61, 121.43, 112.24, 111.37, 109.29, 104.40, 63.58, 40.15, 39.94, 39.73, 39.52, 39.31, 38.89, 14.91, 12.15. HPLC (5 min): tR = 1.59 min, HPLC purity 98%. LC/MS (ESI) *m*/*z*: (M + H)^+^ 307.1; HRMS (EI) *m*/*z*: 306.1368 \[M + H\]^+^ calcd for C~19~H~18~N~2~O~2~, 307.1447; found, 307.1448.

### (*E*)-3-(2-Methyl-5-propoxy-1*H*-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (**2b**) {#sec3.2.4}

2-Methyl-5-propoxy-\[1*H*\]-indole-3-carbaldehyde (80 mg, 0.37 mmol) was reacted following the protocol described for **2a** to yield the corresponding compound as a yellow solid (46.7 mg, 39%): ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.89 (s, 1H), 8.85--8.78 (m, 2H), 8.08 (d, *J* = 15.3 Hz, 1H), 7.96--7.90 (m, 2H), 7.41 (d, *J* = 2.3 Hz, 1H), 7.37--7.27 (m, 2H), 6.85 (dd, *J* = 8.7, 2.3 Hz, 1H), 4.04 (t, *J* = 6.5 Hz, 2H), 2.58 (s, 3H), 1.78 (q, *J* = 6.8 Hz, 2H), 1.03 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 188.15, 154.52, 150.54, 145.66, 145.14, 139.59, 130.94, 126.60, 121.37, 112.89, 112.20, 111.38, 109.23, 104.35, 69.59, 22.23, 12.14, 10.53. HPLC (10 min): tR = 4.27 min, HPLC purity 100%. LC/MS (ESI) *m*/*z*: (M + H)^+^ 321.3; HRMS (EI) *m*/*z*: 321.15973 \[M + H\]^+^ calcd for C~20~H~21~O~2~N~2~, 321.15975; found, 321.15973.

### (*E*)-3-(5-Isopropoxy-2-methyl-1*H*-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (**2c**) {#sec3.2.5}

2-Methyl-5-propoxy-\[1*H*\]-indole-3-carbaldehyde (80 mg, 0.37 mmol) was reacted following the protocol described for **2a** to yield the corresponding compound as an orange solid (2.0 mg, 3%): ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.87 (s, 1H), 8.84--8.79 (m, 2H), 8.06 (d, *J* = 15.3 Hz, 1H), 7.94--7.89 (m, 2H), 7.41 (d, *J* = 2.3 Hz, 1H), 7.34--7.25 (m, 2H), 6.83 (dd, *J* = 8.7, 2.3 Hz, 1H), 4.68 (p, *J* = 6.1 Hz, 1H), 3.30 (s, 4H), 2.56 (s, 3H), 1.30 (d, *J* = 6.0 Hz, 6H). HPLC (5 min): tR = 1.74 min; HPLC purity 100%. LC/MS (ESI) *m*/*z*: \[M + H\]^+^; HRMS (EI) *m*/*z*: 321.2 \[M + H\]^+^ calcd for C~20~H~20~N~2~O~2~, 321.1643; found, 321.1635.

### (*E*)-Ethyl 5-Methoxy-3-(3-oxo-3-(pyridin-4-yl)prop-1-en-1-yl)-\[1*H*\]-indole-2-carboxylate (**2l**) {#sec3.2.6}

Ethyl 3-formyl-5-methoxy-\[1*H*\]-indole-2-carboxylate (50 mg, 0.202 mmol) was reacted following the protocol described for **1a** using piperidine (2 equiv) instead of pyrrolidine to yield the desired product as a yellow solid (61.9 mg, 86%): ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 12.5 (s, 1H), 8.84 (d, *J* = 5.9 Hz, 2H), 8.74 (d, *J* = 16.0 Hz, 1H), 7.93 (d, *J* = 5.9 Hz, 2H), 7.65 (d, *J* = 15.8 Hz, 1H), 7.57--7.47 (m, 2H), 7.09 (d, *J* = 8.9 Hz, 1H), 4.40 (q, *J* = 7.1 Hz, 2H), 3.91 (s, 3H), 1.35 (t, *J* = 7.1 Hz, 3H). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 189.84, 160.68, 155.73, 150.61, 144.44, 139.46, 125.44, 121.58, 116.56, 115.49, 114.50, 103.09, 61.12, 55.55, 14.09. HPLC (10 min): tR = 4.45 min, HPLC purity 100%. LC/MS (ESI) *m*/*z*: 351.3 (M + H)^+^; HRMS (EI) *m*/*z*: 351.13393 \[M + H\]^+^ calcd for C~20~H~19~O~4~N~2~, 351.13393; found, 351.13391.

### Sodium (*E*)-5-Methoxy-3-(3-oxo-3-(pyridin-4-yl)prop-1-en-1-yl)-\[1*H*\]-indole-2-carboxylate (**2o**) {#sec3.2.7}

To a solution of **2l** (20 mg, 0.057 mmol) in tetrahydrofuran/MeOH (2:1, 3 mL), 4 N NaOH (0.071 mL, 0.285 mmol) was added at room temperature and further stirred for 4 h at 50 °C until completion of the reaction. The volatiles were then evaporated under a reduced pressure and cold diethyl ether (10 mL) was added. The resulting precipitate was collected and dried at room temperature for 24 h to yield the desired compound as a red solid sodium salt (15.9 mg, 77%). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 9.32 (d, *J* = 13.7 Hz, 1H), 8.69 (d, *J* = 5.9 Hz, 2H), 7.77 (d, *J* = 5.7 Hz, 2H), 7.31 (d, *J* = 8.5 Hz, 1H), 7.25 (s, 1H), 6.88 (s, 1H), 6.61 (d, *J* = 7.1 Hz, 1H), 3.81 (s, 3H). ^13^C NMR (126 MHz, DMSO-*d*~6~): δ 189.63, 163.52, 155.44, 150.95, 146.13, 145.58, 130.58, 127.05, 122.02, 115.01, 114.01, 112.69, 111.00, 104.30, 55.97. HPLC (10 min): tR = 3.10 min, HPLC purity \>98%. LC/MS (ESI) *m*/*z*: 323.2 (M + H)^+^; HRMS (EI) *m*/*z*: 323.10272 \[M + H\]^+^ calcd for C~18~H~15~O~4~N~2~, 323.10263; found, 323.10272.

Lipid Kinase Competition Assay {#sec3.3}
------------------------------

Lipid kinase competition assay for 22 inositol kinases including clinically relevant mutants were performed using DiscoveRX KINOMEscan profiling. Briefly, streptavidin-coated magnetic beads were treated with biotinylated positive control compounds (compounds that specifically bind each kinase) to generate affinity resins. Binding reactions were performed by combining DNA-tagged kinases, liganded affinity beads, and test compounds. After binding, DNA-tagged kinases were eluted and each kinase concentration in the eluates was measured by qPCR of DNA tag on each kinase.

Cell Viability Assay {#sec3.4}
--------------------

Cells were plated into each well of Greiner 384-well plates at a density of 1500 cells/well. The cells were incubated with increasing concentration of compounds (0.1% v/v DMSO) for 72 h, and cell viability was measured by an EnVison plate reader (PerkinElmer) with CellTiter-Glo (Promega).

Cell Morphology {#sec3.5}
---------------

For acquisition of phase contrast images of live cells, HCT116 cells were seeded on a 384-well high-content imaging microplate. Next day, the compounds were added and images were obtained at the indicated time after the addition of compounds using an EVOS FL Cell Imaging System (Life Technologies, Paisley, UK).

PIKFYVE Inhibition Assay {#sec3.6}
------------------------

The kinase inhibition assay was performed using an ADP-Glo system (Promega) according to the manufacturer protocol. Briefly, the kinase reaction was performed by adding the active PIKFYVE protein (SignalChem), lipid substrate PI(3)P (SignalChem), protein kinase C lipid activator (SignalChem), and 50 μM ATP (SignalChem) in kinase buffer (25 mM MOPS (pH 7.2), 12.5 mM β-glycerol-phosphate, 25 mM MgCl~2~, 5 mM egtazic acid, 2 mM ethylenediaminetetraacetic acid, and 0.25 mM dithiothreitol). The reaction was terminated by adding the ADP-Glo reagent (Promega). The ATP--ADP conversion was quantitated by adding the kinase detection reagent (Promega) and reading the luminescence signal with the plate reader (EnVision).

*PIKFYVE* KnockOut {#sec3.7}
------------------

Pooled *PIKFYVE-/-* cells were generated using CRISPR-Cas9-mediated knockout. HCT116 cells stably expressing Cas9 were transduced with lentivirus containing sgRNA against *PIKFYVE*. sgRNA with a scrambled sequence was used as a control.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00202](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00202).Synthetic protocol scheme, ^1^H NMR spectra, HPLC spectra, and HRMS spectra of compounds **1a**, **2a**, **2b**, **2c**, **2l**, and **2o** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00202/suppl_file/ao8b00202_si_001.pdf))
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